Disruption Of Cdk4/6-Rarα-NF-Κb Axis Attenuates Senescence-Associated Inflammation And Improves Function During Aging And Following Chemotherapy
As we age and undergo treatments like chemotherapy, certain cells in our body can enter a state called senescence. These “senescent cells” don’t divide anymore, but they can release inflammatory signals that contribute to various dysfunctions, including those seen in aging and after cancer treatment. Scientists have discovered that by targeting a specific cellular communication pathway, they can reduce this harmful inflammation. They found that a short-term treatment with a drug called abemaciclib, which inhibits certain proteins (CDK4/6), can effectively quiet these inflammatory signals from senescent cells. This not only lessened the ability of chemotherapy-induced senescent cells to promote tumor growth but also enhanced physical abilities in mice that had received chemotherapy. Further investigation revealed that this drug works by interfering with a signaling route involving retinoic acid and a key inflammatory regulator (NF-κB). Another compound that blocks a component of this pathway (RARα) showed similar beneficial effects. These findings suggest a promising new strategy to improve health during aging and recovery from chemotherapy by modifying the behavior of senescent cells.
Source: link to paper